Endocrinology Drugs Market Size, Share & Industry Analysis, By Drug Class (Diabetes & Metabolic {Insulins, GLP-1 Receptor Agonists, and SGLT2 Inhibitors}, Thyroid {Thyroid Hormones and Antithyroid Agents}, Pituitary {Growth Hormones}, Adrenal {Glucocorticoids}, and Bone Metabolism {Bisphosphonates}), By Disease Indication (Diabetes Mellitus, Obesity, and Thyroid Disorders), By Age Group (Pediatric and Adults), By Route of Administration (Oral, Subcutaneous, Intravenous, and Others), By Distribution Channel (Hospital, Retail, and Specialty Pharmacies), and Regional Forecast, 2026-2034

Last Updated: October 09, 2026 | Format: PDF | Report ID: FBI119383

Buy Now

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2021-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2021-2024
Growth Rate	CAGR of 9.86% from 2026 to 2034
Unit	Value (USD Billion)
Segmentation	By Drug Class, Disease Indications, Age Group, Route of Administration, Distribution Channel, and Region
By Drug Class	Diabetes and Metabolic Drug Classes Insulins & Insulin Analogues GLP-1 Receptor Agonists Dual & Multi-Receptor Agonists SGLT2 Inhibitors Others Thyroid Drug Classes Thyroid Hormones Antithyroid Agents IGF-1 Receptor Inhibitors Others Pituitary and Hypothalamic Drug Classes Growth Hormones Somatostatin Analogues Vasopressin Analogues Dopamine Agonists Others Adrenal Drug Classes Glucocorticoids Mineralocorticoids Steroidogenesis Inhibitors Glucocorticoid Receptor Antagonists & Modulators Others Bone and Mineral Metabolism Drug Classes Bisphosphonates RANKL Inhibitors Parathyroid Hormone & PTHrP Analogues Sclerostin Inhibitors Others Gonadal and Pubertal Drug Classes Androgens Estrogens Progestogens GnRH Agonists Others Other Drug Classes Glucagon & Glucagon Analogues Calcimimetics FGF23 Inhibitors Others
By Disease Indication	Diabetes Mellitus Obesity & Weight Management Thyroid Disorders Osteoporosis & Other Metabolic Bone Disorders Gonadal & Pubertal Disorders Pituitary & Hypothalamic Disorders Adrenal Disorders Others
By Age Group	Pediatric Adults
By Route of Administration	Oral Subcutaneous Intravenous Transdermal Others
By Distribution Channel	Hospital Pharmacies Retail Pharmacies & Drug Stores Specialty Pharmacies Others
By Region	North America (By Drug Class, Disease Indications, Age Group, Route of Administration, Distribution Channel, and Country) U.S. Canada Europe (By Drug Class, Disease Indications, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region) Germany U.K. France Spain Italy Scandinavia Rest of Europe Asia Pacific (By Drug Class, Disease Indications, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region) China Japan India Australia Southeast Asia Rest of Asia Pacific Latin America (By Drug Class, Disease Indications, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region) Brazil Mexico Rest of Latin America Middle East & Africa (By Drug Class, Disease Indications, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region) GCC South Africa Rest of the Middle East & Africa